

1 **Dermal trypanosomes in suspected and confirmed cases of *gambiense* Human**
2 **African Trypanosomiasis.**

3 Mariame Camara¹ (M.D.), Alseny M'mah Soumah^{1,2} (M.D.), Hamidou Ilboulido^{1,3,4} (Ph.D.),
4 Christelle Travaillé⁵ (Ph.D.), Caroline Clucas⁶ (Ph.D.), Anneli Cooper⁶ (Ph.D.), Nono-Raymond
5 Kuispond Swar^{6,7} (M.D.), Oumou Camara¹, Ibrahim Sadissou⁴ (PhD), Estefania Calvo Alvarez⁵
6 (Ph.D.), Aline Crouzols⁵, Jean-Mathieu Bart⁴ (PhD), Vincent Jamonneau⁴ (Ph.D.), Mamadou
7 Camara¹ (Ph.D.), Annette MacLeod^{6*} (Ph.D.), Bruno Bucheton^{1,4*} (Ph.D.) and Brice
8 Rotureau^{5**} (Ph.D.)

9
10 ¹ Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Ministère de la
11 Santé, Conakry, Guinea

12 ² Service de Dermatologie, Hôpital de Donka, Conakry, Guinea

13 ³ Institut de Recherche en Sciences de la Santé (IRSS) - Unité de Recherche Clinique de Nanoro
14 (URCN), Nanoro, Burkina-Faso

15 ⁴ Institut de Recherche pour le Développement, Unité Mixte de Recherche IRD-CIRAD 177
16 InterTryp, Campus International de Baillarguet, Montpellier, France

17 ⁵ Trypanosome Transmission Group, Trypanosome Cell Biology Unit, INSERM U1201 &
18 Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France

19 ⁶ Wellcome Centre for Molecular Parasitology, College of Medical, Veterinary and Life
20 Sciences, Henry Wellcome Building for Comparative Medical Sciences, Glasgow, Scotland,
21 United Kingdom

22 ⁷ Department of Parasitology, National Institute of Biomedical Research (INRB), Kinshasa,
23 Democratic Republic of the Congo

24 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

25 * Joint last authors

26 # Corresponding author: Brice Rotureau, PhD, Trypanosome Transmission Group,

27 Trypanosome Cell Biology Unit, INSERM U1201 & Department of Parasites and Insect Vectors,

28 Institut Pasteur, 25 rue du Docteur Roux, 75015 Paris, France, rotureau@pasteur.fr, Tel +33

29 (0)1 40 61 38 33

30

31 **Short title**

32 Dermal trypanosomes in gHAT cases and suspects

33

34 **Keywords**

35 Skin, reservoir, carriers, Human African Trypanosomiasis, *Trypanosoma brucei gambiense*.

36 **Abstract** (244 words)

37 Background

38 The diagnosis of Human African Trypanosomiasis (HAT) typically involves two steps: a
39 serological screen, followed by the detection of living trypanosome parasites in the blood or
40 lymph node aspirate. Live parasites can, however, remain undetected in some seropositive
41 individuals, who we hypothesize are infected with *Trypanosoma brucei gambiense* parasites
42 in their extravascular dermis.

43 Methods and findings

44 To test this hypothesis, we conducted a prospective observational cohort study in the
45 *gambiense* HAT (gHAT) focus of Forecariah, in the Republic of Guinea. 5,417 subjects in this
46 disease foci underwent serological screening for gHAT. Of these individuals, 66 were enrolled
47 into our study, of whom 40 were seronegative, 8 were seropositive but unconfirmed, and 18
48 confirmed gHAT cases. Enrolled individuals underwent a dermatological examination, and had
49 blood samples and skin biopsies taken and examined for trypanosomes by molecular and
50 immuno-histological methods. In confirmed cases, dermatological symptoms were
51 significantly more frequent, relative to seronegative controls. *T. b. gambiense* parasites were
52 present in the blood of all confirmed cases but not in unconfirmed seropositive individuals.
53 However, trypanosomes were detected in the dermis of all unconfirmed seropositive
54 individuals and confirmed cases. After 6 and 20 months of treatment, dermal trypanosome
55 numbers in skin biopsies of confirmed cases progressively reduced.

56 Conclusions

57 Our results thus highlight the skin as a potential reservoir for trypanosomes, with implications
58 for our understanding of this disease's epidemiology in the context of its planned elimination
59 and highlighting the skin as a novel target for gHAT diagnostics.

60 **Introduction**

61 *Trypanosoma brucei gambiense* is a protist parasite that is transmitted by the bite of the tsetse
62 fly and causes Human African Trypanosomiasis (gHAT, also known as sleeping sickness), in
63 Western and Central Africa [1]. The epidemiological importance of animal reservoirs of
64 trypanosomes is not well-characterized [2] and these parasites are considered to mostly
65 circulate in human populations in discrete endemic foci, with approximately 13 million people
66 at risk [3]. The number of new cases has never been so low in the known epidemiological
67 history of the disease, with only ~1,500 new cases reported in 2017 [4], and the World Health
68 Organization (WHO) has targeted gHAT elimination by 2030 [3]. This objective has been
69 encouraged by the success of active surveillance efforts that relies on a two-step diagnosis:
70 an initial serological screen, followed by microscope observation of blood, lymph or
71 cerebrospinal fluid (CSF) to detect extracellular trypanosomes and to confirm the serological
72 diagnosis. However, some seropositive individuals remain without a confirmed parasitological
73 diagnosis for years. Such, individuals have been recently described as being latent cases,
74 raising the question as to whether reservoirs of live parasites persist in these individuals [5].
75 The role of skin in the transmission of arthropod-borne protozoan parasites has been
76 overlooked for several decades [6]. *T. brucei s. l.* parasites are found in the extravascular
77 compartment of various tissues of their mammalian hosts, including the skin, albeit mostly
78 under experimental conditions in animal models rather than during the natural progression
79 of the disease [7]. Recently, the extravascular tropism of African trypanosomes was re-visited
80 in light of the new molecular and imaging technologies that are now available in animal
81 models [8-10]. Such studies have revealed that substantial quantities of trypanosomes persist
82 within the extravascular dermis following experimental infection in mice with *T. b. gambiense*
83 or *T. b. brucei*. These parasites can be transmitted to the tsetse vector, even in the absence of

84 detectable parasites in the host's blood [9]. This study also reported a retrospective screening
85 of archived skin biopsies from a gHAT endemic region, which revealed the presence of some
86 extravascular skin-dwelling trypanosomes [9]. However, the species of these parasites was
87 not identified and no clinical records were available for the screened samples.
88 These observations raise the question as to whether *T. b. gambiense* might be found in the
89 skin of confirmed gHAT cases, as well as in unconfirmed seropositive individuals, in regions of
90 active disease transmission. To address this question, we performed a prospective
91 observational study in the Forecariah district in the Republic of Guinea, which is one of the
92 most active gHAT foci in Western Africa.

93 **Methods**

94 Ethical approval

95 All investigations were conducted in accordance with the Declaration of Helsinki and fulfil the
96 STROBE criteria. Approval for this study was obtained from the consultative committee for
97 deontology and ethics at the Institut de Recherche pour le Développement and from the
98 National Ethical Committee of the Republic of Guinea (Study Diag-Cut-THA 032/CNERS/17 and
99 amendment 038/CNERS/19).

100 Study enrolment, screening, and case definitions

101 All subjects enrolled in this study came from 43 villages in the active gHAT focus of the
102 Forecariah District, which is located in a coastal mangrove area of the Republic of Guinea and
103 in the HAT National Control Programme Centre of Forecariah [11]. All enrolled subjects were
104 screened from May 2017 to February 2019 in medical surveys performed by the HAT National
105 Control Programme, according to WHO recommendations and as described previously [12]. A
106 total of 5,417 individuals were screened with the card agglutination test for trypanosomiasis
107 using whole blood samples (CATTwb) (Table 1). For those individuals who tested positive in
108 the CATTwb screening test, 5ml of blood was collected in heparinized tubes and a two-fold
109 plasma dilution series was used to determine the CATT plasma (CATTp) end titre. All
110 individuals with CATTp end titres of 1/4 or higher then underwent a microscopic examination
111 of lymph node aspirate, whenever cervical swollen lymph nodes were present. Blood samples
112 of CATTp-positive individuals were also centrifuged to obtain the buffy coat layer, which was
113 tested for trypanosomes using the mini-anion exchange centrifugation test (mAECT BC) [13].
114 If trypanosomes were detected using this test, the infected individual underwent a lumbar
115 puncture and their disease stage was determined by searching for trypanosomes using the
116 modified simple centrifugation technique for CSF and by white blood cell (WBC) counts [14].

117 *Gambiense* HAT patients were classified as being stage 1 (0-5 WBC/ μ l and absence of
118 trypanosomes in CSF) or stage 2 (>5 WBC/ μ l and/or presence of trypanosomes in CSF) and
119 were treated accordingly by the National Control Programme. Treatment consisted of
120 Pentamidine for stage 1 patients (intramuscular injection of 4 mg/kg once daily for 7 days in
121 adults) or Nifurtimox-Eflornithine Combination Therapy (NECT) for stage 2 patients (oral
122 Nifurtimox at 15 mg/kg per day in three doses for 10 days and intravenous Eflornithine (α -
123 difluoromethylornithine or DFMO) at 400 mg/kg per day in two 2h-infusions for 7 days in
124 adults). All parasitologically confirmed cases in this study were diagnosed and treated
125 according to WHO recommendations.

126 All confirmed cases (CATTp $\geq 1/4$ with parasitological confirmation) and all unconfirmed
127 seropositive individuals (CATTp $\geq 1/4$ without parasitological confirmation) were proposed for
128 study enrolment. Seronegative controls were randomly selected, and approximately two age-
129 matched seronegative controls for every seropositive case were enrolled from the same
130 village. Among the 40 seronegative controls, the first 29 individuals enrolled in the study in
131 2017 were only included in the epidemiological and clinical analysis but were not sampled for
132 biological analyses, whereas the last 11 individuals enrolled in 2019 were subjected to the
133 entire protocol, according to the recommendations from the national ethical committee of
134 the Republic of Guinea. In total, 5/8 and 4/8 unconfirmed seropositive individuals were
135 followed-up at 6 months and 20 months after enrolment, respectively, and 17/18 and 12/18
136 confirmed cases were followed-up at 6 months and 20 months after treatment, respectively
137 (Table 4). Children under 16 years of age and pregnant women were excluded from the study.
138 Each participant was informed about the study's objectives in their own language and
139 provided written informed consent. For participants between 16 to 18 years of age, informed

140 consent was also obtained from their parents. The data of individual study participants were
141 randomly anonymized with a 4-digit code at enrolment.

142 Field procedure and sampling

143 At enrolment, each participant underwent an epidemiological interview and a clinical
144 examination, during which dermatological symptoms were assessed by a trained
145 dermatologist (AMS), as well as at each subsequent follow-up at 6 and 20 months after
146 enrolment/treatment. This interview and clinical examination were performed for all
147 confirmed seropositive cases, all unconfirmed seropositive individuals, and for all
148 seronegative controls. The following epidemiological data were collected: age (in years), sex,
149 clinical history of HAT infections in the family since 2010, and occupational risk (occurrence of
150 any regular activities such as farming, hunting, fishing, wood-cutting and/or mining, during
151 which an individual might be more exposed to tsetse bites). The following general clinical data
152 were also collected during the interview: body temperature, presence of swollen cervical
153 lymph nodes, weight loss, asthenia, eating disorders, sexual dysfunctions, repetitive
154 headaches, circadian rhythm disruptions and/or any other behavioural changes during the last
155 three months. Dermatological signs of pruritus (skin itch) and dermatitis (skin inflammation)
156 were also investigated and a careful examination of the entire body was performed, in order
157 to detect any symptoms that might be related to skin infections.

158 Finally, a 2mm blood-free skin punch biopsy was sampled in sterile conditions from the right
159 back shoulder of all confirmed seropositive cases, all unconfirmed seropositive individuals,
160 and for the final 11 seronegative controls. Biopsies were performed under local anaesthesia,
161 and were rapidly dressed. Touch preparations were obtained by gently rolling the biopsy on a
162 clean glass slide. The slides were air-dried, fixed in methyl alcohol, and stained with Giemsa
163 (RAL 555 kit) for microscopic observation in the field. Biopsies were then rapidly fixed in 10%

164 neutral buffered formalin for immuno-histochemistry and molecular analyses. Plasma aliquots
165 from blood samples were also obtained during the screening step for use in serological
166 trypanolysis tests, as described below.

167 Immune trypanolysis test

168 A plasma sample from all confirmed seropositive cases, all unconfirmed seropositive
169 individuals and from the final 11 seronegative controls was used to perform the immune
170 trypanolysis test. This test detects complement-mediated immune responses activated by
171 either the LiTat 1.3, LiTat 1.5 or LiTat 1.6 variable surface antigens specific for *T. b. gambiense*,
172 as previously described [15].

173 Immunohistochemical detection of trypanosomes

174 Skin biopsy samples were fixed in formalin, trimmed and processed into paraffin blocks in the
175 lab. Longitudinal sections of ~2.5µm were then prepared and processed using Dako
176 Autostainer Plus (Dako, Denmark). Sections were stained with haematoxylin-eosin (HE) and
177 Giemsa stains. They were also immunolabelled with the *T. brucei*-specific, anti-ISG65
178 antibody, which targets the Invariant Surface Glycoprotein 65 (rabbit 1/800; gift from M.
179 Carrington, Cambridge, UK) [16], and with the *T. brucei*-specific, anti-Hsp70 antibody, which
180 recognizes the endoplasmic reticulum molecular chaperone heat-shock protein 70 homologue
181 (rabbit 1/2000; gift from J.D. Bangs, Buffalo, USA) [17]. For immunolabelling, the appropriate
182 horseradish peroxidase-coupled secondary antibodies were used, and the staining was
183 revealed with 3,3'-diaminobenzidine and counterstained with Gill's haematoxylin. A non-
184 infected West African skin specimen (Tissue Solutions Ltd., UK) and a *T. b. gambiense*-infected
185 mouse skin specimen were also included with the samples as technical negative and positive
186 controls, respectively. Immunostaining images were acquired using an Axio Observer Z1
187 microscope (Carl Zeiss, Germany) or a Leica 4000B microscope (Leica, Germany), and were

188 analysed using the ImageJ 1.49v software (NIH, USA). In total, all biopsies were analysed in
189 parallel using up to four distinct immuno-histochemical staining. The slides from each biopsy
190 were assessed in a blinded protocol by at least two readers, with results confirmed by up to
191 two more independent trained readers (providing an average of 8 distinct slide reads per
192 subject at enrolment and 4 distinct reads per subject for each follow-up session). Slides from
193 the 11 seronegative controls were randomly mixed with slides from the seropositive cases in
194 order to guarantee blind reading. The positivity of a given skin-section slide was defined by
195 the detection of at least three, clearly distinguishable trypanosomes.

196 DNA extraction

197 Three, 10µm-thick sections were cut from each remaining paraffin- embedded skin specimen,
198 with the blade being changed between samples. A non-infected West African skin specimen
199 (Tissue Solutions Ltd., UK) and a *T. b. gambiense*-infected mouse skin specimen were also
200 included with the samples as negative and positive technical controls, respectively. DNA was
201 then extracted from the sections using Deparaffinization Solution (Qiagen, Germany) and the
202 QIAamp DNA FFPE Tissue Kit (Qiagen, Germany), following the manufacturer's instructions.
203 For blood samples, DNA extraction was performed on 1ml blood aliquots using the DNeasy
204 Tissue kit (Qiagen, Germany), following the manufacturer's recommendations [18].

205 PCR detection of trypanosome DNA

206 PCR detection of *T. brucei s. l.* parasites was performed using published primers, which
207 hybridize to a 177bp DNA satellite repeat sequence (10,000 copies per cell) to generate a
208 117bp amplicon as previously described [19]. All PCR results were confirmed using new
209 primers (TBRN3-F 5'-TAAATGGTTCTTATACGAATGA-3' and TBRN3-R 5'-
210 TTGCACACATTAACACTAAAGAACA-3') that externally flank the first primer pair to generate
211 a larger fragment of 168bp. *T. b. gambiense*-specific PCR directed against the single copy

212 *TgsGP* gene was also performed using published primers (308bp amplicon), as previously
213 described [20], or by using a combination of new (5'-TATGCCGGCTACGGCACCAA-3') and
214 published (5'-GGGCTCCTGCCTCAATTGCTGCA-3') [21] primers in order to reduce the amplicon
215 to 97bp.

216 Data analyses

217 General descriptive analyses of anonymized data were performed using Excel 16.16.11
218 (Microsoft, USA). Statistical analyses were performed using XLSTAT Biomed 2019.2.1
219 (Addinsoft, France) and Prism V.8.3.0 (GraphPad, USA) software. For epidemiological, clinical
220 and diagnostic parameters, differences between seronegative controls versus unconfirmed
221 seropositive individuals and confirmed cases were assessed using the following two-sided
222 tests at 5% confidence: Fisher's exact tests for qualitative data (Tables 2 and 3) and/or Mann-
223 Whitney tests for quantitative data (age in Table 2). For the follow-up analyses, differences
224 between results at enrolment versus results at 6 months and 20 months after
225 treatment/enrolment were assessed for each group using two-sided Fisher's exact tests at 5%
226 confidence (Table 4).

227 **Results**

228 Epidemiological and clinical results

229 5,417 individuals were initially screened using the card agglutination test for trypanosomiasis
230 on whole-blood (CATTwb). For CATTwb-positive individuals, a further CATT test was
231 performed on plasma (CATTp) for serological validation. These tests identified 5,377
232 seronegative individuals (CATTwb-negative or $CATTp < 1/4$), of whom 40 were enrolled as
233 seronegative controls, of whom 11 provided skin biopsies (Table 1). Among seropositive
234 individuals (CATTwb-positive and $CATTp \geq 1/4$), 12 were negative for infection based on
235 parasitological examination (prevalence of 0.22%), 8 of whom were enrolled as non-confirmed
236 seropositive individuals (Table 1). 28 cases were found to be seropositive (CATTwb-positive
237 and $CATTp \geq 1/4$) and further confirmed by parasitological observations (prevalence of 0.52%),
238 including 8 stage-1 and 18 stage-2 cases, of whom 4 stage-1 and 14 stage-2 cases were
239 enrolled as confirmed gHAT cases (Table 1). In total, 66 seronegative and seropositive
240 (confirmed and non-confirmed) individuals were enrolled in this study and were placed into
241 groups, depending on their screening, validation and confirmation results (Table 1).

242 An epidemiological and clinical assessment was performed on all enrolled subjects, including
243 a dermatological assessment (Table 2). None of the four studied epidemiological parameters
244 (age, sex, occupational risk, and clinical history of gHAT in the family) differed significantly
245 between study groups (Table 2). Clinical symptoms such as asthenia ($P < 0.0001$), fever
246 ($P = 0.0013$) and weight loss ($P = 0.0046$) were statistically (Fisher's exact test) more frequent in
247 confirmed cases ($n = 18$), as compared to seronegative controls ($n = 40$) (Table 2). A particularly
248 marked result ($P < 0.0001$) was the presence of swollen cervical lymph nodes in 94% (17/18) of
249 the confirmed cases and in 75% (6/8) of the unconfirmed seropositive cases, as compared to
250 13% (5/39) of the seronegative controls (Table 2).

251 Among the various observed clinical manifestations of localized dermatitis, we unambiguously
252 identified typical cases of intertrigo (in 4/18 confirmed cases versus 2/40 seronegative
253 controls), pityriasis (in 3/18 versus 2/40), scabies (in 3/18 versus 1/40), dermatophytosis (in
254 3/18 versus 1/40), molluscum (in 3/18 versus 1/40), and ulceration (in 3/18 versus 1/40).
255 Apart from general pruritus and intertrigo, all dermatological signs were observed in upper
256 regions of the body, especially on the thorax and arms. Confirmed cases of trypanosomiasis
257 (83%, 15/18) were significantly more frequently affected by any types of dermatitis than were
258 seronegative controls (18%, 7/40) ($P < 0.0001$ by Fisher's exact test) (Table 2). Oedematous
259 faces were observed in four confirmed cases, and a general pruritus was reported in 64%
260 (9/14) of the stage-2 cases, as compared to 5% (2/40) of the seronegative controls. In total,
261 individuals with confirmed cases of gHAT presented with general or localized pruritus
262 significantly more frequently (61%, 11/18) than did seronegative controls (8%, 3/40)
263 ($P < 0.0001$ by Fisher's exact test) (Table 2). For unconfirmed seropositive individuals, an
264 intermediate situation was observed; these individuals had a significantly higher rate of
265 dermatitis (63%, including 1/8 with pityriasis, 2/8 with intertrigo and 3/8 with eczema) relative
266 to seronegative controls (18%, 7/40) ($P = 0.0166$ by Fisher's exact test), but lower than that of
267 confirmed cases (83%, 15/18) (Table 2).

268 Biological results

269 Plasma from all confirmed and unconfirmed seropositive cases, and from the final 11
270 seronegative controls, was assessed using the trypanolysis test, which detects complement-
271 mediated immune responses activated by *T. b. gambiense*-specific antigens. All confirmed
272 cases were positive for the LiTat 1.3 antigen, and 89% (16/18) of these cases were positive for
273 both the LiTat 1.5 and 1.6 antigens (Table 3). These results agree with the serological test
274 results, which indicate that these individuals have an active trypanosome infection, at least in

275 the blood compartment. However, only 25% (2/8) of the unconfirmed seropositive individuals
276 were positive for all antigens; the remainder were negative for all three variants (Table 3).
277 Before a single 2mm skin punch biopsy was sampled from all confirmed and unconfirmed
278 seropositive cases and from 11/40 seronegative controls, the absence of dermatitis lesions at
279 the skin sampling site was verified. Dermal touch preparations were then generated from the
280 biopsy samples, Giemsa-stained and read in the field. Sub-optimal ambient conditions ($31\pm 1^{\circ}\text{C}$
281 at $75\pm 6\%$ humidity on average) during the preparation of these slides meant that their quality
282 was sub-optimal (S1 Fig.). However, full length trypanosomes were observed on slides from
283 81% (13/16) of the clinical cases and from 33% (2/6) of the unconfirmed, seropositive
284 individuals, with these results blindly confirmed by at least two independent slide readers
285 (Table 3 and S1 Fig.). One of the unconfirmed seropositive individuals who tested positive in
286 this dermal test, also tested positive in the trypanolysis test.
287 The skin biopsy samples were then fixed with formalin and later processed for
288 immunohistochemistry analyses (IHC) in the lab. Skin samples obtained from the seronegative
289 controls (11/11) did not test positive for trypanosomes, neither following staining by Giemsa
290 and haematoxylin-eosin (HE) nor for the *T. brucei*-specific antibodies used in this study (Table
291 3). By contrast, all unconfirmed seropositive individuals (8/8) and all confirmed cases (18/18)
292 were found to be positive at least following staining by a *T. brucei*-specific anti-*ISG65* antibody
293 targeting the Invariant Surface Glycoprotein 65 expressed at the surface of the mammalian
294 host stages of *T. brucei s. l.* parasites (Fig. 1, S2 Fig. and Table 3). In addition, all samples from
295 non-confirmed seropositive individuals and confirmed cases were also found to be positive
296 following either unspecific Giemsa staining and/or unspecific HE staining and/or labelling with
297 a *T. brucei*-specific anti-*Hsp70* antibody (Fig. 1, S2 Fig. and Table 3).

298 In positive skin sections, *T. brucei* parasites were evenly distributed in the reticular dermis,
299 and were occasionally associated with oedema. To verify the size of the observed
300 trypanosome cell sections, morphometric measurements were obtained from Giemsa-stained
301 and ISG65-labelled skin-sections (Fig. 1 and S2 Fig.). These measurements show that the mean
302 parasite length was $15.0 \pm 4.1 \mu\text{m}$ (n=293) in Giemsa-stained images and $15.9 \pm 3.7 \mu\text{m}$ (n=109)
303 in ISG65-labelled images.

304 To confirm the identity of these skin-dwelling parasites, *T. brucei*-specific PCR (TBR-PCR)
305 assays were performed on total DNA extracted from fresh blood and from paraffin-embedded
306 skin samples. Both blood and skin DNA samples from the seronegative controls (11/11) were
307 found to be negative for trypanosome DNA by the TBR-PCR assays. By contrast, 100% of blood
308 (18/18) and 78% of skin samples (14/18) from confirmed cases tested positively in the TBR-
309 PCR assays. However, parasite DNA was only detected in the skin of unconfirmed seropositive
310 individuals (75%, 6/8) but not in their blood (0/8) (Table 3). The less sensitive *T. b. gambiense*-
311 specific TgsGP-PCR, which amplifies a single-copy gene, was performed on the same DNA
312 samples and was positive for only 67% (12/18) of the blood samples of confirmed cases (Table
313 3). We reasoned that the use of fresh skin biopsies would be more appropriate for TgsGP-PCR.
314 To test this hypothesis, we therefore obtained fresh skin samples, conserved in stabilization
315 buffer, from an outgroup of nine additional confirmed cases, who were identified in 2018
316 using the same study protocol and who were living in the same district (S1 Table). These fresh
317 skin samples from 89% (8/9) of these confirmed cases were found to be positive for
318 trypanosome infection by TBR-PCR, while three cases (33%) were also found to be positive by
319 TgsGP-PCR (S1 Table).

320 Follow-up results

321 The same panel of analyses were repeated at 6 and 20 months after study enrolment of the
322 unconfirmed seropositive individuals, and at 6 and 20 months after treatment of the
323 confirmed cases (Table 4). Most of the clinical symptoms associated with the stage-2 cases at
324 enrolment significantly decreased in frequency during the first 6 months after treatment
325 (Table 4). A similar trend was observed for the stage-1 cases, with a statistically significant
326 decrease in the frequency of dermatitis 20 months after treatment (P=0.0286 by Fisher's exact
327 test) (Table 4). The clearance of parasites from the blood and skin of all stage-2 cases who
328 were followed-up at 20 months after treatment was assessed by a statistically significant
329 reduction (Fisher's exact test) in the number of positive results from the following assays:
330 CATTwb (from 13/13 at enrolment to 4/9 at 20 months, P=0.0048), CATTp (from 13/13 to 0/9,
331 P<0.0001), parasitological examination of body fluids (from 13/13 to 0/9, P<0.0001),
332 trypanolysis test (from 13/13 to 5/9 LiTat1.3-positive, P=0.0172), TBR-PCR assays on blood
333 (from 13/13 to 0/9, P<0.0001) and skin (from 12/13 to 0/9, P<0.0001), and by IHC analyses
334 following labelling with an anti-Hsp70 antibody (from 11/12 to 0/9, P<0.0001) and an anti-
335 ISG65 antibody (from 13/13 to 0/9, P<0.0001) (Table 4). Parasitological observations and PCR
336 results became negative within 6 months of treatment in all confirmed cases (17/17) (Table
337 4). Twenty months after treatment, all confirmed cases (12/12) returned a negative result in
338 the trypanolysis test against LiTat 1.6 and in the IHC analyses of skin sections (Table 4).
339 However, at the end of the study, 67% (2/3) of the stage-1 cases and 44% (4/9) of the stage-2
340 cases still had positive results in the CATTwb test, and 100% (3/3) of the stage-1 cases and
341 56% (5/9) of the stage-2 cases, still had positive results in the trypanolysis test against LiTat
342 1.3 (Table 4). In addition, swollen lymph nodes were still detectable in 2 out of 3 stage-1 and
343 in 3 out of 9 stage-2 cases (Table 4). For the 5 unconfirmed seropositive individuals who were

344 monitored after enrolment, no obvious variations were observed in any of their clinical
345 parameters over time (Table 4). Although 2 out of 4 unconfirmed seropositive individuals were
346 found to still be positive for CATTp 20 months after enrolment, their TBR-PCR results on skin
347 DNA and IHC staining results became negative over time. Of the six individuals who were in
348 the unconfirmed seropositive group (n=8), and who tested positive for dermal trypanosomes
349 by both TBR-PCR and IHC analyses at enrolment, three were lost for follow-up before 6
350 months (due to one death, one pregnancy and one resignation). In addition, the unconfirmed
351 seropositive subject, who was still positive after 6 months for the CATTp, the trypanolysis test
352 and the skin biopsy IHC with the anti-ISG65 antibody, refused to participate at the 20 months
353 follow-up. However, during an active surveillance campaign in November 2019 (i.e. after the
354 end of this study), this individual was diagnosed as being a stage-1 confirmed case (CATTwb
355 +, CATTp 1/8, mAECT BC +, CSF - and WBC 4) and was treated accordingly.

356 **Discussion**

357 Here, we set out to investigate whether *T. b. gambiense* parasites might be found in the skin
358 of confirmed gHAT cases, as well as in unconfirmed seropositive individuals, in regions of
359 active disease transmission. Although this study is somewhat limited to a restricted population
360 and to the detection methods used, 100% of the confirmed cases and unconfirmed
361 seropositive subjects were found to carry extravascular trypanosomes in their skin.

362 Detection of trypanosomes

363 Routine molecular analyses by TBR-PCR confirmed the presence of *T. brucei s. l.* parasites in
364 both the blood and skin of confirmed cases. However, parasite DNA was only detected in the
365 skin of unconfirmed seropositive individuals, which might underlie their infectious status in
366 the extravascular compartment. In contrast, no positive results were found by *T. b.*
367 *gambiense*-specific TgsGP-PCR on DNA extracted from paraffin-embedded skin samples, likely
368 due to the low sensitivity of this method, which targets a single-copy gene. However, the
369 positivity of some direct TgsGP-PCR assays, performed on fresh skin DNA samples from an
370 outgroup of confirmed cases, suggests that the trypanosomes found in the dermis of the
371 confirmed cases enrolled in the present study are likely to be *T. b. gambiense* parasites.

372 The trypanolysis test results were also compatible with previous reports [12]. Nevertheless, it
373 is noteworthy that, within the limits of the method used, 6 out of 8 unconfirmed seropositive
374 subjects gave a negative trypanolysis test result, despite the presence of skin-dwelling
375 parasites in these individuals, as confirmed by histological approaches. In 2 of these
376 unconfirmed seropositive subjects who had a positive trypanolysis test result, trypanosomes
377 were also detected in their skin samples by at least 2 distinct histological approaches and by
378 PCR. These observations suggest that unconfirmed seropositive subjects who have negative
379 trypanolysis test results carry trypanosomes in the extravascular compartment. In addition,

380 although anti-LiTat1.3 antibodies were detected by CATT in the plasma of these unconfirmed
381 seropositive subjects, the trypanolytic activity of these anti-LiTat1.3 antibodies appeared
382 limited as assessed by the negativity of the corresponding trypanolysis tests. The apparent
383 lack of congruence between results of the CATTp and of the trypanolysis test is possibly
384 reflecting a peculiar status of the immune response in some non-confirmed seropositive
385 subjects that remained to be studied more in-depth.

386 Dermatological signs in gHAT

387 Our results indicate that dermatological symptoms might be an important aspect of gHAT's
388 clinical presentation. The few reports that exist on this topic in the literature describe a wide
389 array of skin pathologies associated with sleeping sickness, including pruritus, chancre, rashes
390 and localized oedemas [22, 23]. However, detailed dermatological profiles of HAT cases have
391 mostly been derived from light-skinned travellers with imported HAT, who apparently
392 experience a more rapid disease onset and more skin manifestations than do dark-skinned
393 African patients [23]. Whereas chancres and rashes remain anecdotal, pruritus was the most
394 commonly observed dermatological sign in endemic cases (this condition is present in up to
395 57% of stage-2 cases) [23]. In our study, we observed a higher occurrence of pruritus and
396 dermatitis in unconfirmed seropositive individuals and in confirmed cases, relative to
397 seronegative controls (Table 2). The observed dermatitis profiles included some conditions
398 the aetiologies of which might not be directly related to a trypanosome infection. However, it
399 could be hypothesized that the immune status of the infected host skin is somehow altered
400 by the presence of trypanosomes in a way that promotes the outcome of dermatitis caused
401 by other pathogens and/or increases skin sensitivity. The direct detection of trypanosomes in
402 the human skin is not well documented in the literature [22]. In our immunohistochemical
403 analyses of skin sections, only a limited portion of each parasite cell is visible, because entire

404 trypanosomes do not necessarily lie in the same plane as the 2.5µm skin sections. For the same
405 reason, the parasite nucleus, kinetoplast and flagellum are rarely all visible in the same given
406 cell section. However, the specificity of the anti-ISG65 and anti-Hsp70 antibodies used in this
407 study enabled the slide readers to unambiguously detect most trypanosomes within the
408 extracellular dermal matrix in a blinded analysis of skin samples. The detection of skin-
409 dwelling parasites at enrolment in most of the 2mm skin punch biopsies sampled from
410 seropositive individuals indicates that skin-dwelling parasites might be present over a
411 considerable proportion of the skin surface. In this study, the choice of the sampling site was
412 guided by preliminary observations recorded in the clinical files of previously confirmed cases
413 in the same region; these cases presented with pruritus more frequently in the upper regions
414 of the body. We reasoned that these bouts of itching could have been provoked by dermal
415 trypanosomes, hence the choice of the right shoulder as the skin sampling site in this study.
416 However, the precise dynamics of parasite load and distribution in the extravascular dermal
417 compartment over the course of an infection remains unknown. According to historic
418 (reviewed in [7]) and more recent [9] studies in experimental animal models, skin-dwelling
419 parasites could theoretically be detected in almost the entire skin surface, yet with a variable
420 distribution and at variable local densities.

421 A dermal reservoir of trypanosomes in non-confirmed seropositive individuals

422 One possible explanation for the persistence of disease foci in certain regions is the presence
423 of animal reservoirs [2]. Another possibility, as increasing evidence suggests, is that
424 traditionally used diagnostic approaches do not detect some *T. b. gambiense* infections among
425 seropositive cases [2]. Indeed, bloodstream parasite numbers in *T. b. gambiense* infections
426 can periodically fluctuate to less than 100 trypanosomes/ml, falling below the detection limit
427 of the most sensitive methods currently in use [24]. Another study estimated that 20-30% of

428 gHAT cases are missed in active case detection by standard parasitological techniques and are
429 left untreated [25]. These infected individuals might ultimately progress to clinical disease or
430 remain almost asymptomatic until undergoing a possible self-cure [2]. Here, for the first time,
431 we provide parasitological evidence for the presence of trypanosomes in eight unconfirmed
432 seropositive subjects. The presence of trypanosomes in the skin of these individuals suggests
433 that the human reservoir of gHAT might be greater than initially thought. In this study, the
434 negative test and assay results obtained on samples from the five unconfirmed seropositive
435 subjects who were followed-up at 20 months suggest that these individuals might have been
436 enrolled during a transient/ending/self-curing infection. In this context, data on the infectious
437 status of the 3 remaining unconfirmed seropositive subjects who were found to have dermal
438 trypanosomes at enrolment, but who were lost from follow-up, would have been informative.
439 However, there remains the case of the unconfirmed seropositive individual, who remained
440 positive for dermal parasites 6 months after enrolment, and who was diagnosed as a
441 confirmed stage-1 case in an active screening campaign 31 months after enrolment, after this
442 study had ended. This individual's diagnosis suggests that dermal parasites could play a
443 significant role during the early stage of the disease.

444 Transmission and epidemiological contribution of dermal trypanosomes

445 Mathematical modelling recently predicted that, in the absence of any animal reservoirs,
446 these unconfirmed seropositive individuals could contribute to disease transmission by
447 maintaining an overlooked reservoir of skin-dwelling parasites [26]. Tsetse feed by lacerating
448 the skin of their host rather than by inserting a proboscis directly into the vasculature. After
449 causing significant local damage at the bite site, the insects ingest the resultant pool of
450 capillary blood and lymph mixed with the surrounding dermal material. Bearing in mind this
451 feeding mechanism and the observation that latent cases host dermal trypanosomes, the skin

452 of such individuals could provide a population of infective parasites that are readily accessible
453 to the tsetse fly. Indeed, this mode of transmission has been demonstrated in experimental
454 animal models, in which skin-dwelling trypanosomes were efficiently transmitted to the tsetse
455 vector, even in the absence of detectable parasitaemia [8, 9, 27]. However, the presence of
456 the parasite forms (called stumpy trypanosome stages) that are assumed to be most adapted
457 for development in tsetse flies were not investigated here. This is an important question for
458 future studies to address, in order to estimate the actual infectivity potential of human skin-
459 dwelling parasites. Our reported observations should also be confirmed in a larger number of
460 unconfirmed seropositive individuals and seronegative controls, and the study scaled-up to
461 include other endemic transmission foci in Africa, in order to confidently determine the actual
462 prevalence of dermal trypanosomes.

463 Conclusion

464 Our results also raise questions about the strategies used to diagnose this disease, which
465 currently focus on detecting parasites in the blood and lymph. If the human skin is indeed a
466 disease reservoir, it could represent a novel target for diagnostics, and it could: (i) allow more
467 carriers to be treated; (ii) help to determine a more accurate estimate of the true prevalence
468 of the disease; and (iii) help to identify as yet undetected reservoirs in both human and animal
469 populations. The current WHO recommendation, based on risk-benefit analyses, is to not treat
470 unconfirmed seropositive individuals without knowing if they have an active infection [1].
471 Importantly, we observed that the routinely administered trypanocide treatments
472 (Pentamidine for stage-1 and NECT for stage-2 cases, according to the previous WHO
473 recommendations) efficiently targeted both bloodstream and dermal trypanosomes in all the
474 patients followed-up, as shown by the negative results of all the tests used in this study after
475 20 months. With the promise of new cheaper, less toxic and easier to administer drugs on the

476 horizon, the policy of treating unconfirmed seropositive individuals could possibly be
477 reconsidered. Indeed, the drug Acoziborole, which requires a single oral administration, could
478 hopefully be the next revolutionary treatment against gHAT. As gHAT approaches its
479 elimination targets, we propose from our findings that current algorithms, which are used to
480 identify and manage disease cases, could be adapted to include the detection of skin-dwelling
481 parasites, which likely represent a previously unaccounted for anatomical reservoir.

482

483

484 **Acknowledgements**

485 We thank M. Carrington (Cambridge, UK) and J.D. Bangs (Buffalo, USA) for providing
486 antibodies. We are grateful to Y. Madec (Paris, France) for his help in statistical analysis. We
487 warmly thank the team of the Programme National de Lutte contre la Trypanosomiase
488 Humaine Africaine of Conakry, as well as all our collaborators of the Forecariah District Health
489 Department. We thank Dominique N'Diaye (Paris, France) for his critical reading and Jane
490 Alfred (Catalyst Editorial, UK) for her editorial work on the manuscript.

491 **Financial disclosure**

492 This work was supported by the Wellcome Trust (209511/Z/17/Z), the Institut de Recherche
493 pour le Développement, the Institut Pasteur, the French Government Investissement d'Avenir
494 programme - Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases"
495 (ANR-10-LABX-62-IBEID) and the French National Agency for Scientific Research (projects
496 ANR-14-CE14-0019-01 EnTrypa and ANR-18-CE15-0012 TrypaDerm). None of these funding
497 sources has a direct scientific or editorial role in the present study.

498 **Author contributions**

499 MarC, AMS and NRKS conducted the clinical study in the field and commented on the
500 manuscript. HI, IS, CT, CC, ACo, ACr, OC, ECA and JMB performed sample analyses and
501 commented on the manuscript. MamC and VJ held logistical aspects, analysed part of the data
502 and commented on the manuscript. AML*, BB* and BR* designed the study, organised
503 logistical aspects, analysed the data and wrote the manuscript as co-last authors.

504 **Competing interest**

505 All authors declare no financial relationships with any organisations that might have an
506 interest in the submitted work in the previous three years, no other relationships nor activities

507 that could appear to have influenced the submitted work, and no other relationships or
508 activities that could appear to have influenced the submitted work.

509 **Data and material availability**

510 Upon request, the original protocol and associated forms, as well as an anonymised dataset,
511 could be obtained from the corresponding author rotureau@pasteur.fr.

512 **Transparency statement**

513 The lead author affirms that the manuscript is an honest, accurate and transparent account
514 of the study being reported, that no important aspect of the study has been omitted, and that
515 any discrepancies from the study as originally planned have been explained.

516 **References**

- 517 1. Buscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. *Lancet*.
518 2017. doi: 10.1016/S0140-6736(17)31510-6. PubMed PMID: 28673422.
- 519 2. Informal Expert Group on *gambiense* HAT, Buscher P, Bart JM, Boelaert M, Bucheton
520 B, Cecchi G, et al. Do Cryptic Reservoirs Threaten *gambiense*-Sleeping Sickness Elimination?
521 *Trends Parasitol*. 2018;34(3):197-207. Epub 2018/02/06. doi: 10.1016/j.pt.2017.11.008.
522 PubMed PMID: 29396200; PubMed Central PMCID: PMC5840517.
- 523 3. Franco JR, Cecchi G, Priotto G, Paone M, Diarra A, Grout L, et al. Monitoring the
524 elimination of human African trypanosomiasis: Update to 2016. *PLoS Negl Trop Dis*.
525 2018;12(12):e0006890. Epub 2018/12/07. doi: 10.1371/journal.pntd.0006890. PubMed
526 PMID: 30521525.
- 527 4. Lindner AK, Lejon V, Chappuis F, Seixas J, Kazumba L, Barrett MP, et al. New WHO
528 guidelines for treatment of *gambiense* human African trypanosomiasis including fexinidazole:
529 substantial changes for clinical practice. *Lancet Infect Dis*. 2020;20(2):e38-e46. Epub
530 2019/12/28. doi: 10.1016/S1473-3099(19)30612-7. PubMed PMID: 31879061.
- 531 5. Berthier D, Breniere SF, Bras-Goncalves R, Lemesre JL, Jamonneau V, Solano P, et al.
532 Tolerance to Trypanosomatids: A Threat, or a Key for Disease Elimination? *Trends Parasitol*.
533 2016;32(2):157-68. doi: 10.1016/j.pt.2015.11.001. PubMed PMID: 26643519.
- 534 6. De Niz M, Meehan GR, Brancucci NMB, Marti M, Rotureau B, Figueiredo LM, et al.
535 Intravital imaging of host-parasite interactions in skin and adipose tissues. *Cell Microbiol*.
536 2019;21(5):e13023. Epub 2019/03/03. doi: 10.1111/cmi.13023. PubMed PMID: 30825872;
537 PubMed Central PMCID: PMC6590052.
- 538 7. Goodwin LG. The pathology of African trypanosomiasis. *Trans R Soc Trop Med Hyg*.
539 1970;64(6):797-817. Epub 1970/01/01. PubMed PMID: 5495630.

- 540 8. Caljon G, Van Reet N, De Trez C, Vermeersch M, Perez-Morga D, Van Den Abbeele J.
541 The Dermis as a Delivery Site of *Trypanosoma brucei* for Tsetse Flies. PLoS Pathog.
542 2016;12(7):e1005744. doi: 10.1371/journal.ppat.1005744. PubMed PMID: 27441553;
543 PubMed Central PMCID: PMC4956260.
- 544 9. Capewell P, Cren-Travaille C, Marchesi F, Johnston P, Clucas C, Benson RA, et al. The
545 skin is a significant but overlooked anatomical reservoir for vector-borne African
546 trypanosomes. eLife. 2016;5. doi: 10.7554/eLife.17716. PubMed PMID: 27653219; PubMed
547 Central PMCID: PMC4956260.
- 548 10. Trindade S, Rijo-Ferreira F, Carvalho T, Pinto-Neves D, Guegan F, Aresta-Branco F, et
549 al. *Trypanosoma brucei* Parasites Occupy and Functionally Adapt to the Adipose Tissue in
550 Mice. Cell Host Microbe. 2016. doi: 10.1016/j.chom.2016.05.002. PubMed PMID: 27237364.
- 551 11. Courtin F, Jamonneau V, Camara M, Camara O, Coulibaly B, Diarra A, et al. A
552 geographical approach to identify sleeping sickness risk factors in a mangrove ecosystem. Trop
553 Med Int Health. 2010;15(8):881-9. doi: 10.1111/j.1365-3156.2010.02559.x. PubMed PMID:
554 20545924.
- 555 12. Ilboudo H, Jamonneau V, Camara M, Camara O, Dama E, Leno M, et al. Diversity of
556 response to *Trypanosoma brucei gambiense* infections in the Forecariah mangrove focus
557 (Guinea): perspectives for a better control of sleeping sickness. Microbes Infect.
558 2011;13(11):943-52. doi: 10.1016/j.micinf.2011.05.007. PubMed PMID: 21658462.
- 559 13. Camara M, Camara O, Ilboudo H, Sakande H, Kabore J, N'Dri L, et al. Sleeping sickness
560 diagnosis: use of buffy coats improves the sensitivity of the mini anion exchange
561 centrifugation test. Trop Med Int Health. 2010;15(7):796-9. doi: 10.1111/j.1365-
562 3156.2010.02546.x. PubMed PMID: 20497407.

- 563 14. Miezán TW, Meda HA, Doua F, Dje NN, Lejon V, Buscher P. Single centrifugation of
564 cerebrospinal fluid in a sealed pasteur pipette for simple, rapid and sensitive detection of
565 trypanosomes. *Trans R Soc Trop Med Hyg.* 2000;94(3):293. Epub 2000/09/07. PubMed PMID:
566 10975002.
- 567 15. Van Meirvenne N, Magnus E, Buscher P. Evaluation of variant specific trypanolysis tests
568 for serodiagnosis of human infections with *Trypanosoma brucei gambiense*. *Acta Trop.*
569 1995;60(3):189-99. Epub 1995/12/01. PubMed PMID: 8907397.
- 570 16. Ziegelbauer K, Overath P. Organization of two invariant surface glycoproteins in the
571 surface coat of *Trypanosoma brucei*. *Infect Immun.* 1993;61(11):4540-5. Epub 1993/11/01.
572 PubMed PMID: 8406850; PubMed Central PMCID: PMCPMC281202.
- 573 17. McDowell MA, Ransom DM, Bangs JD. Glycosylphosphatidylinositol-dependent
574 secretory transport in *Trypanosoma brucei*. *Biochem J.* 1998;335 (Pt 3):681-9. Epub
575 1998/10/31. PubMed PMID: 9794811; PubMed Central PMCID: PMCPMC1219832.
- 576 18. Koffi M, Solano P, Denizot M, Courtin D, Garcia A, Lejon V, et al. Aparasitemic
577 serological suspects in *Trypanosoma brucei gambiense* human African trypanosomiasis: a
578 potential human reservoir of parasites? *Acta Trop.* 2006;98(2):183-8. doi:
579 10.1016/j.actatropica.2006.04.001. PubMed PMID: 16723098.
- 580 19. Cunningham LJ, Lingley JK, Haines LR, Ndung'u JM, Torr SJ, Adams ER. Illuminating the
581 Prevalence of *Trypanosoma brucei s.l.* in *Glossina* Using LAMP as a Tool for Xenomonitoring.
582 *PLoS Negl Trop Dis.* 2016;10(2):e0004441. Epub 2016/02/20. doi:
583 10.1371/journal.pntd.0004441. PubMed PMID: 26890882; PubMed Central PMCID:
584 PMCPMC4758712.


- 585 20. Radwanska M, Claes F, Magez S, Magnus E, Perez-Morga D, Pays E, et al. Novel primer
586 sequences for polymerase chain reaction-based detection of *Trypanosoma brucei gambiense*.
587 Am J Trop Med Hyg. 2002;67(3):289-95. Epub 2002/11/01. PubMed PMID: 12408669.
- 588 21. Morrison LJ, Tait A, McCormack G, Sweeney L, Black A, Truc P, et al. *Trypanosoma*
589 *brucei gambiense* Type 1 populations from human patients are clonal and display geographical
590 genetic differentiation. Infect Genet Evol. 2008;8(6):847-54. Epub 2008/09/16. doi:
591 10.1016/j.meegid.2008.08.005. PubMed PMID: 18790085.
- 592 22. McGovern TW, Williams W, Fitzpatrick JE, Cetron MS, Hepburn BC, Gentry RH.
593 Cutaneous manifestations of African trypanosomiasis. Arch Dermatol. 1995;131(10):1178-82.
594 PubMed PMID: 7574836.
- 595 23. Blum JA, Neumayr AL, Hatz CF. Human African trypanosomiasis in endemic populations
596 and travellers. Eur J Clin Microbiol Infect Dis. 2012;31(6):905-13. Epub 2011/09/09. doi:
597 10.1007/s10096-011-1403-y. PubMed PMID: 21901632.
- 598 24. Buscher P, Deborggraeve S. How can molecular diagnostics contribute to the
599 elimination of human African trypanosomiasis? Expert Rev Mol Diagn. 2015;15(5):607-15. doi:
600 10.1586/14737159.2015.1027195. PubMed PMID: 25786994.
- 601 25. Robays J, Bilengue MM, Van der Stuyft P, Boelaert M. The effectiveness of active
602 population screening and treatment for sleeping sickness control in the Democratic Republic
603 of Congo. Trop Med Int Health. 2004;9(5):542-50. doi: 10.1111/j.1365-3156.2004.01240.x.
604 PubMed PMID: 15117297.
- 605 26. Capewell P, Atkins K, Weir W, Jamonneau V, Camara M, Clucas C, et al. Resolving the
606 apparent transmission paradox of African sleeping sickness. PLoS Biol. 2019;17(1):e3000105.
607 Epub 2019/01/12. doi: 10.1371/journal.pbio.3000105. PubMed PMID: 30633739.

608 27. Wombou Toukam CM, Solano P, Bengaly Z, Jamonneau V, Bucheton B. Experimental
609 evaluation of xenodiagnosis to detect trypanosomes at low parasitaemia levels in infected
610 hosts. *Parasite*. 2011;18(4):295-302. PubMed PMID: 22091459; PubMed Central PMCID:
611 PMC3677595.
612

613 **Figures**

614 **Fig. 1. Extravascular trypanosomes in the dermal matrix of human skin biopsies.**

615 For each enrolled study subject, paraffin-embedded skin biopsy sections were stained either
616 with (A) a specific anti-ISG65 antibody (brown) or (B) with Giemsa (purple) and screened at a
617 100x magnification. Representative trypanosome sections from confirmed stage-1 (subject
618 1044) and stage-2 cases (subjects 1035, 1036, 1037, 1039 and 1042), as well as from
619 unconfirmed seropositive individuals (subjects 1046, 1065 and 1066) are shown. The scale
620 bars represent 10 μ m. More images of extravascular *T. brucei* parasites in human skin biopsies
621 are available in S2 Fig.



622

623 **Supporting information legends**

624 **S1 Fig. Giemsa-stained skin biopsy touch-preparations showing trypanosomes among**
625 **extracellular dermal matrix elements.** For most of the enrolled seropositive subjects, blood-
626 free skin biopsy touch-preps were directly stained with Giemsa in the field and scrutinized at
627 a 100x magnification. Scale bars represent 10µm and white arrows indicate dermal
628 trypanosomes.

629 **S2 Fig. Pictures of skin biopsy sections with different immuno-histological staining showing**
630 **extravascular *T. brucei* parasites in the dermal matrix of both unconfirmed seropositive**
631 **individuals and confirmed cases.** For each enrolled subject identified by a 4-digit code,
632 paraffin-embedded skin biopsy sections were either counterstained with Giemsa, HE, an anti-
633 ISG65 antibody or an anti-Hsp70 antibody and scrutinized at a 100x magnification. Scale bars
634 represent 10µm and white arrows indicate dermal trypanosome sections.

635 **S1 Table. Detailed serological and molecular analysis results from blood and skin samples of**
636 **additional confirmed cases.** CATTwb / CATTp: card agglutination test for trypanosomiasis on
637 whole blood / plasma; mAECT BC: mini anion-exchange column technic on buffy coat; PCR:
638 single round polymerase chain reaction; TgsGP: *Trypanosoma brucei gambiense* surface
639 glycoprotein; +: positive result; -: negative result.

640

641 **Tables**

642 **Table 1. Diagnostic process, number of subjects and results.**

643 CATTwb / CATTp: card agglutination test for trypanosomiasis on whole blood / plasma; mAECT

644 BC / LN aspirate: mini anion-exchange column technique on buffy coat / lymph node aspirate;

645 WBC: white blood cells; CSF: cerebrospinal fluid; ND: not determined. *Highest plasma

646 dilution with a positive result.

647

648

Groups	Diagnostic process				No. subjects			
	1- Serological screening	2- Serological validation	3- Parasitological confirmation	4- Staging	Screened	Enrolled	Followed-up	
	CATTwb / RDT	CATTp*	mAECT BC / LN aspirate observation	Parasites in CSF	No. WBC in CSF			
Seronegative	- +	ND < 1/4	ND	ND	ND	5 377	40	0
Seropositive	+	≥ 1/4	-	ND	ND	12	8	5
Stage 1				no	0-5	8	4	4
Stage 2	+	≥ 1/4	+	yes	>5	18	14	13
ND					ND	2	0	0
All						28	18	17
Total						5 417	66	22

649 **Table 2. Epidemiological and clinical characteristics of case subjects.**

650 For each group and each parameter, total values correspond to the numbers of subjects for
651 which a value was available (n/total). p values were obtained by comparing one by one the
652 parameters of each group of seropositive subjects (unconfirmed and all confirmed) to those
653 of seronegative controls using two-sided Fisher's exact tests or * two-sided Mann-Whitney
654 tests at 5% confidence. LN: lymph nodes.

655

Parameters	Groups (n=66)					
	Seronegative (n=40)	Seropositive (n=8)	Confirmed (n=18)			p values
			Stage 1 (n=4)	Stage 2 (n=14)	All (n=18)	
	n/total (%) or mean (SD)	n/total (%) or mean (SD)	n/total (%) or mean (SD)	n/total (%) or mean (SD)	n/total (%) or mean (SD)	
Epidemiological						
Age (n=66)	37.9 (14)	36.6 (18)	31.0 (17)	35.6 (15)	34.6 (15)	0.3502*
Male sex (n=66)	22/40 (55%)	3/8 (38%)	2/4 (50%)	5/14 (36%)	7/18 (39%)	0.3950
HAT case(s) in the family since 2010 (n=65)	11/40 (28%)	2/7 (29%)	2/4 (50%)	5/14 (36%)	7/18 (39%)	0.5404
Occupational risk (n=66)	17/40 (43%)	4/8 (50%)	2/4 (50%)	5/14 (36%)	7/18 (39%)	>0.9999
Clinical						
Swollen LN (n=65)	5/39 (13%)	6/8 (75%)	4/4 (100%)	13/14 (93%)	17/18 (94%)	0.0010
Any dermatological symptoms (n=66)	8/40 (20%)	5/8 (63%)	4/4 (100%)	13/14 (93%)	17/18 (94%)	0.0252
Dermatitis (n=66)	7/40 (18%)	5/8 (63%)	4/4 (100%)	11/14 (79%)	15/18 (83%)	0.0166
Pruritus (n=66)	3/40 (8%)	2/8 (25%)	0/4 (0%)	11/14 (79%)	11/18 (61%)	0.1887
Asthenia (n=65)	17/39 (44%)	4/8 (50%)	4/4 (100%)	14/14 (100%)	18/18 (100%)	>0.9999
Fever (n=63)	6/38 (16%)	1/7 (14%)	2/4 (50%)	9/14 (64%)	11/18 (61%)	>0.9999
Weight loss (n=61)	6/39 (15%)	3/8 (38%)	2/4 (50%)	6/10 (60%)	8/14 (57%)	0.1672
Eating disorders (n=66)	4/40 (10%)	1/8 (13%)	0/4 (0%)	7/14 (50%)	7/18 (39%)	>0.9999
Headache (n=65)	23/39 (59%)	6/8 (75%)	3/4 (75%)	13/14 (93%)	16/18 (89%)	0.6918
Circadian rhythm disruptions (n=66)	3/40 (8%)	1/8 (13%)	0/4 (0%)	5/14 (36%)	5/18 (28%)	0.5303
Sexual dysfunctions (n=65)	4/39 (10%)	1/8 (13%)	0/4 (0%)	5/14 (36%)	5/18 (28%)	>0.9999
Behaviour changes (n=63)	4/39 (10%)	0/7 (0%)	0/4 (0%)	3/13 (23%)	3/17 (18%)	>0.9999

657 **Table 3. Serological, molecular and histological analysis results from blood and skin samples.**

658 For each group and each parameter, total values correspond to the numbers of subjects for
659 which a value was available (n/total). p values were obtained by comparing one by one the
660 parameters of each group of seropositive subjects (unconfirmed and all confirmed) to those
661 of seronegative controls using two-sided Fisher's exact tests at 5% confidence. VAT: variable
662 antigen type; PCR: polymerase chain reaction; TgsGP: *Trypanosoma brucei gambiense* surface
663 glycoprotein; HE: haematoxylin-eosin; IHC: immuno-histochemistry; Hsp70: heat shock
664 protein 70; ISG65: invariant surface glycoprotein 65; ND: not determined.

665

Parameters	Groups (n=37)						
	Seronegative (n=11)	Seropositive (n=8)	Confirmed (n=18)			p values	
			Stage 1 (n=4)	Stage 2 (n=14)	All (n=18)		
	n/total (%)	n/total (%)	n/total (%)	n/total (%)	n/total (%)	p values	
Trypanolysis	LiTat 1.3 positive (n=36)	0/10 (0%)	2/8 (25%)	4/4 (100%)	14/14 (100%)	18/18 (100%)	<0.0001
	LiTat 1.5 positive (n=36)	0/10 (0%)	2/8 (25%)	4/4 (100%)	12/14 (86%)	16/18 (89%)	<0.0001
	LiTat 1.6 positive (n=36)	0/10 (0%)	2/8 (25%)	4/4 (100%)	12/14 (86%)	16/18 (89%)	<0.0001
	Positive for all VATs (n=36)	0/10 (0%)	2/8 (25%)	4/4 (100%)	12/14 (86%)	16/18 (89%)	<0.0001
	Negative for all VATs (n=36)	10/10 (100%)	6/8 (75%)	0/4 (0%)	0/14 (0%)	0/18 (0%)	<0.0001
PCR on blood	TBR positive (n=37)	0/11 (0%)	0/8 (0%)	4/4 (100%)	14/14 (100%)	18/18 (100%)	<0.0001
	TgsGP positive (n=37)	0/11 (0%)	0/8 (0%)	2/4 (50%)	10/14 (71%)	12/18 (67%)	0.0004
	Negative for all PCRs on blood (n=37)	11/11 (100%)	8/8 (100%)	0/4 (0%)	0/14 (0%)	0/18 (0%)	<0.0001
PCR on skin	TBR positive (n=37)	0/11 (0%)	6/8 (75%)	1/4 (25%)	13/14 (93%)	14/18 (78%)	<0.0001
	TgsGP positive (n=37)	0/11 (0%)	0/8 (0%)	0/4 (0%)	0/14 (0%)	0/18 (0%)	>0.9999
	Negative for all PCRs on skin (n=37)	11/11 (100%)	2/8 (25%)	3/4 (75%)	1/14 (7%)	4/18 (22%)	<0.0001
Histology	Dermal touchpreps (n=22, 3 reads)	ND	2/6 (33%)	1/3 (33%)	12/13 (92%)	13/16 (81%)	
	HE section (n=36, 1 read)	0/11 (0%)	6/8 (75%)	4/4 (100%)	8/13 (62%)	12/17 (71%)	0.0003
	Giemsa section (n=37, 2 reads)	0/11 (0%)	4/8 (50%)	0/4 (0%)	14/14 (100%)	14/18 (78%)	<0.0001
	IHC Hsp70 (n=31, 1 read)	0/11 (0%)	1/4 (25%)	1/4 (25%)	11/12 (92%)	12/16 (75%)	0.0002
	IHC ISG65 (n=37, 3 reads)	0/11 (0%)	8/8 (100%)	4/4 (100%)	14/14 (100%)	18/18 (100%)	<0.0001
	Negative for all reads (n=37)	11/11 (100%)	0/8 (0%)	0/4 (0%)	0/17 (0%)	0/18 (0%)	<0.0001

667 **Table 4. Clinical, serological, molecular and histological follow-up analyses at 6 and 20**
668 **months after enrolment.**

669 Total values correspond to the numbers of subjects for which a value was available (n/total).
670 For each group of subjects, p values were obtained by comparing one by one the parameters
671 recorded at 6 months and 20 months after treatment/enrolment to those obtained at
672 enrolment, using two- sided Fisher's exact tests at 5% confidence. LN: lymph nodes; CATT:
673 card agglutination test for trypanosomiasis; VAT: variable antigen type; PCR: TBR polymerase
674 chain reaction; Hsp70: heat shock protein 70; ISG65: invariant surface glycoprotein 65; ND:
675 not determined.

Parameters	Confirmed																	
	Seropositive						Stage 1						Stage 2					
	Enrollment	6 months	20 months	Enrollment	6 months	20 months	Enrollment	6 months	20 months	Enrollment	6 months	20 months	Enrollment	6 months	20 months			
n/total (%)	n/total (%)	p values	n/total (%)	n/total (%)	p values	n/total (%)	n/total (%)	p values	n/total (%)	n/total (%)	p values	n/total (%)	n/total (%)	p values	n/total (%)	p values		
Clinics	Asthenia	3/5 (60%)	1/5 (20%)	0.5238	2/4 (50%)	>0.9999	4/4 (100%)	0/4 (0%)	0.0286	2/3 (67%)	0.4286	13/13 (100%)	3/13 (23%)	0.0001	3/9 (33%)	0.0011		
	Swollen LN	4/5 (80%)	1/4 (25%)	0.2063	3/4 (75%)	>0.9999	4/4 (100%)	2/3 (67%)	0.4286	2/3 (67%)	0.4286	12/13 (92%)	2/11 (18%)	0.0005	3/9 (33%)	0.0066		
	Any dermatological symptoms	4/5 (80%)	1/5 (20%)	0.2063	1/4 (25%)	0.2063	4/4 (100%)	1/4 (25%)	0.1429	0/3 (0%)	0.0286	12/13 (92%)	5/13 (38%)	0.0112	3/9 (33%)	0.0066		
	Fever	1/5 (20%)	1/5 (20%)	>0.9999	0/4 (0%)	>0.9999	2/4 (50%)	0/4 (0%)	0.4286	0/3 (0%)	0.4286	9/13 (69%)	0/13 (0%)	0.0005	1/9 (11%)	0.0115		
	Headache	5/5 (100%)	2/5 (40%)	0.1667	3/4 (75%)	0.4444	3/4 (75%)	0/4 (0%)	0.1429	0/3 (0%)	0.1429	12/13 (92%)	2/13 (15%)	0.0002	4/9 (44%)	0.0231		
	Pruritus	1/5 (20%)	0/5 (0%)	>0.9999	1/4 (25%)	>0.9999	0/4 (0%)	0/4 (0%)	>0.9999	0/3 (0%)	>0.9999	10/13 (77%)	3/13 (23%)	0.0169	2/9 (22%)	0.0274		
	Weight loss	2/5 (40%)	2/5 (40%)	>0.9999	0/4 (0%)	0.4444	2/4 (50%)	1/4 (25%)	>0.9999	0/3 (0%)	0.4286	5/9 (56%)	0/13 (0%)	0.0048	0/9 (0%)	0.0294		
	Dermatitis	4/5 (80%)	1/5 (20%)	0.2063	1/4 (25%)	0.2063	4/4 (100%)	1/4 (25%)	0.1429	0/3 (0%)	0.0286	10/13 (77%)	5/13 (38%)	0.1107	3/9 (33%)	0.0789		
	Eating disorders	1/5 (20%)	1/5 (20%)	>0.9999	1/4 (25%)	>0.9999	0/4 (0%)	0/4 (0%)	>0.9999	0/3 (0%)	>0.9999	6/13 (46%)	0/13 (0%)	0.0149	1/9 (11%)	0.1649		
	Sexual dysfunctions	1/5 (20%)	3/5 (60%)	0.5238	0/4 (0%)	>0.9999	0/4 (0%)	0/4 (0%)	>0.9999	0/3 (0%)	>0.9999	5/13 (38%)	5/13 (38%)	>0.9999	1/9 (11%)	0.3330		
	Circadian rhythm disruptions	1/5 (20%)	1/5 (20%)	>0.9999	0/4 (0%)	>0.9999	0/4 (0%)	0/4 (0%)	>0.9999	0/3 (0%)	>0.9999	4/13 (31%)	1/13 (8%)	0.3217	1/9 (11%)	0.3602		
	Behaviour changes	0/4 (0%)	1/5 (20%)	>0.9999	0/4 (0%)	>0.9999	0/4 (0%)	0/4 (0%)	>0.9999	0/3 (0%)	>0.9999	2/12 (17%)	0/13 (0%)	0.2200	0/9 (0%)	0.4857		
	CATTwb	5/5 (100%)	4/5 (80%)	>0.9999	3/4 (75%)	0.4444	4/4 (100%)	4/4 (100%)	>0.9999	2/3 (67%)	0.4286	13/13 (100%)	10/13 (77%)	0.2200	4/9 (44%)	0.0048		
	CATTp	5/5 (100%)	1/5 (20%)	0.0476	2/4 (50%)	0.1667	4/4 (100%)	4/4 (100%)	0.0286	1/3 (33%)	0.1429	13/13 (100%)	3/13 (23%)	0.0001	0/9 (0%)	<0.0001		
	Parasitology	0/5 (0%)	0/5 (0%)	>0.9999	0/4 (0%)	>0.9999	4/4 (100%)	4/4 (100%)	0.0286	0/3 (0%)	0.0286	13/13 (100%)	0/13 (0%)	<0.0001	0/9 (0%)	<0.0001		
Trypanolysis	LiTat 1.3 positive	1/5 (20%)	1/5 (20%)	>0.9999	0/4 (0%)	>0.9999	4/4 (100%)	>0.9999	3/3 (100%)	>0.9999	10/11 (91%)	0.2200	5/9 (56%)	0.0172				
	LiTat 1.5 positive	1/5 (20%)	1/5 (20%)	>0.9999	0/4 (0%)	>0.9999	4/4 (100%)	>0.9999	2/3 (67%)	0.4286	11/13 (85%)	8/11 (73%)	0.6299	5/9 (56%)	0.1778			
	LiTat 1.6 positive	1/5 (20%)	1/5 (20%)	>0.9999	0/4 (0%)	>0.9999	4/4 (100%)	>0.9999	0/3 (0%)	0.0286	11/13 (85%)	6/11 (54%)	0.1819	0/9 (0%)	0.0002			
	Positive for all VATs	1/5 (20%)	1/5 (20%)	>0.9999	0/4 (0%)	>0.9999	4/4 (100%)	>0.9999	0/3 (0%)	0.0286	11/13 (85%)	6/11 (54%)	0.1819	0/9 (0%)	0.0002			
Negative for all VATs	4/5 (80%)	4/5 (80%)	>0.9999	4/4 (100%)	>0.9999	0/4 (0%)	0/4 (0%)	>0.9999	0/3 (0%)	>0.9999	0/13 (0%)	1/11 (9%)	0.4583	3/9 (33%)	0.0545			
TBR PCR	Blood	0/5 (0%)	0/5 (0%)	>0.9999	0/4 (0%)	>0.9999	4/4 (100%)	0/4 (0%)	0.0286	0/3 (0%)	0.0286	13/13 (100%)	0/13 (0%)	<0.0001	0/9 (0%)	<0.0001		
	Skin	3/5 (60%)	0/5 (0%)	0.1667	0/4 (0%)	0.1667	1/4 (25%)	0/4 (0%)	>0.9999	0/3 (0%)	>0.9999	12/13 (92%)	0/13 (0%)	<0.0001	0/9 (0%)	<0.0001		
Histology	Dermal touchpreps	1/3 (33%)	0/2 (0%)	>0.9999	ND	ND	1/3 (33%)	>0.9999	ND	ND	11/12 (92%)	2/13 (15%)	0.0002	ND	ND			
	IHC Hsp 70	1/4 (25%)	ND	>0.9999	0/4 (0%)	>0.9999	1/4 (25%)	ND	0/3 (0%)	>0.9999	11/12 (92%)	ND	ND	0/9 (0%)	<0.0001			
	IHC ISG65	5/5 (100%)	1/5 (20%)	0.0476	0/4 (0%)	0.0079	4/4 (100%)	0/4 (0%)	0.0286	0/3 (0%)	0.0286	13/13 (100%)	5/13 (38%)	0.0016	0/9 (0%)	<0.0001		
	Negative for all reads	0/5 (0%)	2/5 (40%)	0.4444	4/4 (100%)	0.0079	0/4 (0%)	2/4 (50%)	0.4286	2/3 (67%)	0.1429	0/13 (0%)	1/13 (8%)	>0.9999	9/9 (100%)	<0.0001		